Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 400 participants.

Also called NCT02426944

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02426944
Other papers using this trial's data
  • 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation Journal of the American College of Cardiology, 2022-01-04 DOI, PubMed 34748929
  • Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation Journal of the American College of Cardiology, 2020-06-30 DOI, PubMed 32586585

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02426944. Randomized; no masking; primary purpose prevention. Start 2015-10-13 (actual); primary completion 2019-07-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation
Acronym
PRAGUE-17
Intervention (Drug)
NOAC
Intervention (Device)
Left atrial appendage closure
Lead sponsor
Charles University, Czech Republic (class: other)
Collaborator
Ministry of Health, Czech Republic (class: other government)

Record details

Record id
cardio:ct-nct02426944
Content hash
c3f7da45e32582c133f6e5c6cde103b050be122a021ed47509ff608b43f6a6a0